SCHEMBL18486383

SCHEMBL18486383

CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H]2O[Si](C(C)(C)C)(C(C)(C)C)OC[C@H]2O[C@H]1n1cnc2c(/C=C/c3ccccc3)ncnc21

nearest known ligand 0.35

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 6/20 0.35
▸ P2RY12 Q9H244 9/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ PDE4A P27815 2/20 0.32
▸ PDE4B Q07343 2/20 0.32
▸ PDE4C Q08493 2/20 0.32
▸ PDE4D Q08499 2/20 0.32
▸ ADORA1 P30542 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18486384 1.00 STING1 (0.35) STING1P2RY12CYP1A2PDE4APDE4B
SCHEMBL17363609 0.91 STING1 (0.34) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL16871715 0.91 STING1 (0.34) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL18486404 0.86 PDE4A (0.34) PDE4APDE4BPDE4CPDE4D
SCHEMBL18486251 0.86 PDE4A (0.34) PDE4APDE4BPDE4CPDE4D
SCHEMBL16871895 0.83 DNPH1 (0.44) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL17363663 0.83 DNPH1 (0.44) STING1PDE4APDE4BPDE4CPDE4D
SCHEMBL17363528 0.83 PDE4A (0.44) STING1CYP1A2PDE4APDE4BPDE4C
SCHEMBL17363529 0.83 PDE4A (0.44) STING1CYP1A2PDE4APDE4BPDE4C
SCHEMBL19689068 0.82 STING1 (0.38) STING1CYP1A2PDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3130597-B1 OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL KYOWA KIRIN CO LTD (JP) 2021-11-10 — — EP disclosed
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 — — US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 — — US disclosed
EP-3130597-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF Kyowa Hakko Kirin Co., Ltd. (JP) 2017-02-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof RNGTT, UPF1, NSUN3 STING1 1024/4885P2RY12 3118/4885CYP1A2 1890/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 STING1 1050/4885P2RY12 3171/4885CYP1A2 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback